Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Archemix and Lilly in Aptamer deal

This article was originally published in Scrip

Executive Summary

Archemix and Lilly are to explore the development of new aptamer-based drugs. The US biotechnology company will license certain IP rights from Lilly, which in return has an option to evaluate aptamers for certain drug targets. Lilly retains an option to enter into an exclusive licence with Archemix for up to two of the aptamer targets. No financial details were disclosed. Aptamers are synthetically derived oligonucleotides (short nucleic acid sequences) that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021688

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel